Literature DB >> 32444922

Local Intra-arterial Vasodilator Infusion in Non-Occlusive Mesenteric Ischemia Significantly Increases Survival Rate.

Robert Winzer1, Dieter Fedders2, Moritz Backes2, Till Ittermann3, Matthias Gründling4, Birger Mensel5, Hanns-Christoph Held6, Marie-Luise Kromrey7, Jürgen Weitz6, Ralf-Thorsten Hoffmann2, Robin Bülow7, Jens-Peter Kühn2.   

Abstract

PURPOSE: To investigate the outcome of local intra-arterial papaverine infusion therapy in patients with non-occlusive mesenteric ischemia (NOMI), and factors influencing survival, in comparison with a conservative approach.
METHODS: From 2013 to 2019, patients with NOMI confirmed by imaging were included in a retrospective two-center study. According to different in-house standard procedures, patients were treated in each center either conservatively or interventionally by a standardized local infusion of intra-arterial papaverine into the splanchnic arteries. Thirty-day mortality and factors influencing the outcome, such as different demographics and laboratories, were compared between groups using Kaplan-Meier survival analysis and Cox regression, respectively.
RESULTS: A total of 66 patients with NOMI were included, with n = 35 treated interventionally (21 males, mean age 67.7 ± 12.3 years) and n = 31 treated conservatively (18 females, mean age 71.6 ± 9.6 years). There was a significant difference in 30-day mortality between the interventional (65.7%; 12/35 survived) and the conservative group (96.8%; 1/31 survived) (hazard ratio 2.44; P = 0.005). Thresholds associated with a worse outcome of interventional therapy are > 7.68 mmol/l for lactate, < 7.31 for pH and <  - 4.55 for base excess.
CONCLUSION: Local intra-arterial papaverine infusion therapy in patients with NOMI significantly increases survival rate in comparison with conservative treatment. High lactate levels, low pH and high base excess, and high demand for catecholamines are associated with a poor outcome. LEVEL OF EVIDENCE: Level III.

Entities:  

Keywords:  Infusion therapy; Mesenteric ischemia; Non-occlusive mesenteric ischemia; Papaverine; Patient outcome assessment

Mesh:

Substances:

Year:  2020        PMID: 32444922     DOI: 10.1007/s00270-020-02515-4

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  2 in total

1.  Interactions of dipyridamole and adenosine on platelet aggregation.

Authors:  R B Philp; J P Lemieux
Journal:  Nature       Date:  1969-03-22       Impact factor: 49.962

2.  [Treatment of benign prostate hypertrophy using Prostatron: a study of the effects of treatment temperature elevation].

Authors:  N R Netto Júnior; J A Claro
Journal:  Prog Urol       Date:  1995-04       Impact factor: 0.915

  2 in total
  4 in total

1.  Nonocclusive mesenteric ischemia caused by type B aortic dissection: a case report.

Authors:  Mengchao Sheng; Wei Gong; Kui Zhao; Wei Li; Aimin Qian; Liuhui Chang; Yongyou Wu; Qiang Chen; Zhengrong Chen; Xiaodong Yang; Fengyun Zhong; Chungen Xing
Journal:  BMC Surg       Date:  2022-06-03       Impact factor: 2.030

2.  Nonocclusive Mesenteric Ischemia Is a Potentially Lethal Complication Just after Stroke Onset: Report of Six Case Studies.

Authors:  Eitaro Okumura; Hiroyuki Jimbo; Shigeki Sunaga; Kunitoshi Otsuka; Hirofumi Okada; Toshiaki Onitsuka
Journal:  NMC Case Rep J       Date:  2021-09-16

3.  Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study.

Authors:  Nina Rittgerodt; Thorben Pape; Sascha David; Klaus Stahl; Markus Busch; Lena S Becker; Andrea Schneider; Heiner Wedemeyer; Benjamin Seeliger; Julius Schmidt; Anna Maria Hunkemöller; Jan Fuge; Wolfgang Knitsch; Christine Fegbeutel; Hans-Jörg Gillmann; Bernhard C Meyer; Marius M Hoeper; Jan B Hinrichs
Journal:  Crit Care       Date:  2022-04-04       Impact factor: 9.097

4.  Monitoring the Sequential Organ Failure Assessment score in nonocclusive mesenteric ischemia increases the survival rate: A single-center observational study.

Authors:  Takaaki Murata; Jun Kawachi; Yuto Igarashi; Yuma Suno; Tomoki Nishida; Katsunori Miyake; Naoko Isogai; Ryuta Fukai; Hiroyuki Kashiwagi; Rai Shimoyama; Masahiro Hirata; Nobuaki Shinozaki
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.